When using the CCR5 inhibitors maraviroc and vicriviroc, the infiltration and invasion of breast cancer cells were reduced; this study also revealed that the invasion ability of CCR5+ cells isolated from breast cancer cells was 40 times greater than that of CCR5-cells [20]. Here, CCR5 is linked to breast carcinoma.